3Q17 Botox addendum: The US-therapeutic figure of $368.9M in #msg-135855769 includes $16.8M of US sales for hyperhidrosis. (AGN’s PR lists the US hyperhidrosis sales separately from other US therapeutic sales.)
• US therapeutic†: $384.0M (+4% YoY) • US cosmetic: $228.4M (+15% YoY) • Ex-US therapeutic: $96.9M (+11% YoY in local currency) • Ex-US cosmetic: $155.0M (+20% YoY in local currency)
All told, 71% of Botox sales were in the US, where the therapeutic/cosmetic split was 63/37; 29% of Botox sales were ex-US, where the therapeutic/cosmetic split was 38/62.
†Includes $16.9M sales for hyperhidrosis.
*The large 4Q17 increase vs 3Q17 was expected; for cosmetic indications, the second and fourth quarters are seasonally stronger than the first and third quarters.
Market Data 
Markets 
AI
